Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.
Lisa M. Barroilhet, MD
Advertisement
Articles by Lisa M. Barroilhet, MD
PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.
Advertisement
Latest Updated Articles
PARP Inhibitors Are Changing Diagnostic and Therapeutic Landscape in Ovarian CancerPublished: August 16th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5